- ►diabetesjournals.org [PDF] ES Horton, C Clinkingbeard, M Gatlin, J Foley … - Diabetes Care, 2000 - Am Diabetes Assoc From the Joslin Diabetes Center (ESH), Boston, Massachusetts; the Idaho
Endocrine Specialists (CC), Boise, Idaho; the Cardiovascular, Metabolic and
Endocrine Department (MG, SM), Clinical Research Divi- sion; and the ... Cited by 201 - Related articles - BL Direct - All 9 versions
M Hanefeld, KP Bouter, S Dickinson, C … - Diabetes Care, 2000 - Am Diabetes Assoc F rom the Outpatient Department, Institute of Clinical Metabolic Research,
Medical Faculty, Technical Uni- versity of Dresden (MH), Dresden, Germany; Bosch
Medicentre (KPB), Den Bosch, the Netherlands; and N ova rtis Pharma AG (SD, ... Cited by 147 - Related articles - BL Direct - All 7 versions
R Moses, R Slobodniuk, S Boyages, S Colagiuri … - Diabetes Care, 1999 - Am Diabetes Assoc I n the US, there are 7 million people with diagnosed type 2 diabetes (1).
Within the first 10 years of diagnosis, mo re than half of all those with type 2
dia- betes take oral hypoglycemic agents (2). ... Between 1970 and 1995, ... Cited by 208 - Related articles - BL Direct - All 7 versions
- ►endojournals.org L Keilson, S Mather, YH Walter, S … - Journal of Clinical Endocrinology & Metabolism, 2000 - Endocrine Soc This study assessed the synergistic effects of nateglinide (a nonsulfonylurea
D-phenylalanine derivative) and meals on insulin secretion in 24 patients with
type 2 diabetes. Oral doses of 60 and 180 mg or 120 and 240 mg were ... Cited by 90 - Related articles - BL Direct - All 5 versions
PA Hollander, SL Schwartz, MR Gatlin, SJ … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—During the liquid-meal challenge, nateglinide reduced the incremental
glucose area under the curve (AUC) more effectively than glyburide (Δ = −4.94
vs. −2.71 mmol · h/l, P < 0.05), whereas glyburide reduced fasting ... Cited by 100 - Related articles - BL Direct - All 7 versions
- ►aspetjournals.org S Hu, S Wang, B Fanelli, PA Bell, BE Dunning … - Journal of Pharmacology and Experimental …, 2000 - ASPET Nateglinide (A-4166) is an amino acid derivative with insulinotrophic action in
clinical development for treatment of type 2 diabetes. The aim of this study was
to determine whether nateglinide's interaction at the K ATP ... Cited by 115 - Related articles - BL Direct - All 3 versions
Y Hirschberg, AH Karara, AO Pietri, JF Mc … - Diabetes Care, 2000 - Am Diabetes Assoc Subjects Ta rget enrollment comprised 12 male and female volunteers with type2
diabetes of at least 6 months' duration, between ages 30 and 70 years, within 10
to 60% of their normal weight range, with an HbA 1 c of 12.5%, and with ... Cited by 60 - Related articles - BL Direct - All 4 versions
M Marre, L Van Gaal, KH Usadel, M Ball, I … - Diabetes Obesity and Metabolism, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 44 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org [PDF] RB Goldberg, D Einhorn, CP Lucas, MS … - Diabetes Care, 1998 - Am Diabetes Assoc Repaglinide versus placebo in type 2 diabetes trial was conducted at five US
medical cen- ters. After an initial screening followed by a 2-week washout
period, eligible patients were randomized to receive either repaglin- ide ... Cited by 128 - Related articles - BL Direct - All 5 versions
